---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-018292"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:20:12.018391+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Curis Q1 net loss $16.1M; cash $120.7M; emavusertib studies on partial clinical hold

## Summary
- Net loss $16.1M ($0.18/sh) vs $9.9M in Q1 2021; revenue $2.1M unchanged.
- Cash and investments $120.7M; runway into 2024, guidance unchanged.
- FDA partial clinical hold on TakeAim Leukemia and Lymphoma studies for emavusertib due to rhabdomyolysis data request.
- TakeAim Leukemia data: 40% CR/CRh in spliceosome-mutated AML; 57% ORR in spliceosome-mutated MDS.
- CI-8993 (anti-VISTA) dose escalation cleared 0.3mg/kg; now at 0.6mg/kg; RP2D yet to be determined.

## SEC filing metadata
- accession: 0001564590-22-018292
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000156459022018292/0001564590-22-018292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000156459022018292/cris-8k_20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-018292
- JSON: https://secwatch.observer/filing/0001564590-22-018292.json
- Plain text: https://secwatch.observer/filing/0001564590-22-018292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.